HELPING THE OTHERS REALIZE THE ADVANTAGES OF ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC)

In Phase C, members will obtain ABBV-744 and oral navitoclax. In Phase D, participants will receive ABBV-744 and ruxolitinib. Members will receive treatment till disease progression or even the contributors are not able to tolerate the study drugs.- "Our study exposed the essential part of your KLF16/MYC regulatory axis in modulating tumor advancem